No Data
Shaanxi Panlong Pharmaceutical Group Forms JV
Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Five-year Earnings Growth Trails the Shareholder Returns
Panlong Pharmaceutical: Report for the third quarter of 2024
Shaanxi Panlong Pharmaceutical (002864.SZ): The net income for the first three quarters was 89.5717 million yuan, an increase of 6.50% year-on-year.
Ge Longhui October 27th | Shaanxi Panlong Pharmaceutical (002864.SZ) announced that in the first three quarters of 2024, revenue reached 0.717 billion yuan, a year-on-year increase of 0.10%; net income attributable to shareholders of the listed company was 89.5717 million yuan, a year-on-year increase of 6.50%, with basic earnings per share of 0.85 yuan.
Shaanxi Panlong Pharmaceutical (002864.SZ) announced its performance for the first three quarters, with a net income of 89.5717 million yuan, a year-on-year increase of 6.50%.
Shaanxi Panlong Pharmaceutical (002864.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Shaanxi Panlong Pharmaceutical (002864.SZ): Considering expanding the number of existing 48 mainstream products to 72.
Gelonghui October 22nd | Shaanxi Panlong Pharmaceutical (002864.SZ) stated at an investor relations event that the traditional chinese medicine industry has now entered the third batch of centralized procurement, and the company's core products are not included in this round of centralized procurement. Faced with this trend of centralized procurement, the company will proactively adapt and respond positively. On the one hand, the company will focus on cost reduction, practice diligently, and reduce energy consumption; on the other hand, the company will start with product strategy, considering expanding the number of existing 48 mainstream products to 72, and adjusting market channel strategy, with "safety compliance" as the guideline to ensure the interests of investors.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Popularity With Investors Under Threat As Stock Sinks 26%
